Micro RNA as Biomarkers and Tool for Target-Based Treatment in Patients with Inflammatory Bowel Diseases

Alexander E Berezin and Eugene I Poplyonkin

Introduction

Ulcerative colitis (UC) and Crohn’s disease (CD) are the most frequently seen inflammatory bowel diseases (IBD), which have similar morphopathogenesis, but they are recognized as diseases that are distinguished sites affected the gastrointestinal tract and outside areas [1,2]. Although prevalence rates of IBD is variant in different countries, the chronic relapsing-remitting inflammatory disorders affecting primarily the gastrointestinal tract arise worldwide [3]. In fact, the importance of genetic risk factors in IBD development is high and it has been documented more clearly for CD than for UC [4]. Moreover, genetic risk factors added to age-related factors, female gender, obesity, current symptoms, and histopathology stages significantly associated with a reduced quality of life, body image dissatisfaction, and disability [5-8]. Therefore, patients with IBM are at significant higher risk for colorectal dysplasia, cancer, bleeding, cachexia, as well as extra intestinal manifestations, such as rheumatoid arthritis [9,10].

Pathogenesis of IBD is difficult, multi faces, complex, and is not fully understood [11]. Therefore, it has been suggested that exiting genetic polymorphism affected nucleotide oligomerization domain 2 (NOD2), tumor necrosis factor (TNF)-SF15, interleukin-23-type 17 helper T-cell (Th17) genes, and appropriate autophagy genes strongly contributes in T-helper-1 and T-helper-2-dependent impairment of immune signaling processes in Crohn’s disease and ulcerative colitis respectively [12-14]. Defective regulation of adaptive immunity may initiate disorders in cell-to-cell cooperation, transferring information, tissue repair mediating, angiogenesis and neovascularization [15-17]. Indeed, crosstalk between epithelial cells, macrophages and dendritic cells plays a pivotal role in gut homeostasis [18-20]. The leading factors contributed in intercellular communication between immune cells and mediated in post-transcriptable regulation of cell function are miRNA-mRNA interactions [21]. The aim of the mini review is summary of knowledge regarding role of miRNA in IBD development.

MicroRNA: Definition and Biological Function

miRNAs have emerged small endogenous single stranded non-coding molecules of RNA (about 15-22 nucleotides) that are able to regulate gene expression at the post-transcription level [22,23]. Currently miRNA are recognized as uniquely important regulators of a variety of physiological and pathological processes including cell growth, proliferation, differentiation, apoptosis, angiogenesis, and malignancy [24,25]. The process of regulation gene expression is mediated through intracellular miRNA-related degradation and translational repression of mRNA [26]. Despite miRNAs are considered ubiquitous and essential targeting specific messengers for miRNAs, one miRNA is able to target hundreds of mRNAs, and, however, one molecule of miRNA can be repressed by more than one miRNA [27]. Although intracellular mechanisms for the regulation of miRNA-mRNA interactions are universal, there is limited tissue specificity regarding transcription factors and nuclear proteins represented with miRNA [28]. Apart from intracellular miRNAs, there are wide spectrum extracellular and circulating miRNAs that are predominantly derived by microvesicles [29]. These miRNAs are able to mediate a broad range of processes affected degradation and translational repression of mRNA transcripts. Moreover, miRNAs were found as basic regulator of cellular functions including secretion and motility, which are crucial for development of both angiogenesis and malignancy. miRNAs may contribute inhibition and/or activation of cell responses to specific stimuli by coordination and transduction of intracellular signals beyond transcript modulation. Potent function of circulating and vesicle-encapsulated miRNAs is reported in Table 1. Theoretically capacity of miRNAs to regulate systemic and localized mechanisms of signaling pathways may depend on their origin, package into microvesicles, molecular composition of cell-derived microvesicles, presentation in microvesicles protected from degradation by lipid bilayer proteins and lipids, and other factors.
Overall intracellular-derived and circulating miRNAs are considered mediators of cell-to-cell cross talk and they play a pivotal role in immune cell cooperation, growth signaling, apoptosis and tissue repair [30]. Interestingly, packaging of miRNAs from cells into microvesicles aimed extracellular transport can be altered by various diseases, i.e. IBD. In fact, ischemia, hypoxia, direct cell injury are consider potent stimul of inflammatory signaling pathways promoted angiogenesis, tissue repair and malignancy.

Therefore, oxidative stress is a causal factor and key promoter of a variety of inflammatory diseases associated with apoptotic cell death by causing deregulation of related genes directly associated with miRNAs synthesis and secretion.

### Table 1: Potent function of circulating extracellular and microvesicle-encapsulated miRNAs.

<table>
<thead>
<tr>
<th>Features</th>
<th>Circulating extracellular miRNAs</th>
<th>Microvesicle-encapsulated miRNAs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proportion in healthy subjects</td>
<td>90-95%</td>
<td>5-10%</td>
</tr>
<tr>
<td>Expected proportion in IBD patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechanism of delivery</td>
<td>secretion</td>
<td>package into vesicles</td>
</tr>
<tr>
<td>Transport modality</td>
<td>free load through circulation</td>
<td>vesicle encapsulation to achieving target cells</td>
</tr>
<tr>
<td>Targeting of signals</td>
<td>systemic</td>
<td>localized</td>
</tr>
<tr>
<td>Angiogenic potency</td>
<td>+</td>
<td>***</td>
</tr>
<tr>
<td>Tissue repair modality (proliferation, cell growth, differentiation)</td>
<td>±</td>
<td>+++</td>
</tr>
<tr>
<td>Malignancy coordination</td>
<td>**</td>
<td>*</td>
</tr>
<tr>
<td>Mechanism of cellular communication</td>
<td>distant</td>
<td>local</td>
</tr>
</tbody>
</table>

However, the exact innate mechanisms of unassisted delivery of miRNAs are still poorly understood and required more investigations. Recent investigations have established that the levels of miRNAs are modulated by cell signaling mechanisms, including the bone-related morphogenetic protein signaling pathway, PI3K/Akt, and p56-MAP kinase regulators, JAK2/STAT3-dependent signaling, Hypoxia-Inducible Factor-1-related mechanisms, nuclear factor kappa B signaling, and etc. [28-32]. Recently in vivo and in vitro studies have presented evidence evidence regarding that miRNA secretion and transfer may dysregulate by several signals, such as inflammatory cytokines, apoptotic intermediates and soluble apoptotic receptors [21,25,27].

### miRNA in Inflammatory Bowel Disease

Recent studies have shown that miRNAs acting as negative regulators of gene expression, which are involved in intestinal inflammation among patients with IBD [33]. Therefore, miRNAs play a pivotal role in regulation of intestinal barrier dysfunction that is suitable for IBD [34,35] and they serve as biomarkers of malignancy and tumorgenesis in this patient population [36]. Whether spectrum of miRNAs is useful for detecting of IBD exacerbation is not fully understood. Table 2 is reported summarized data regarding the role of miRNAs in IBD.

Alterations inmiRNA expression with overlap between different isoforms of miRNAs were identified for IBD. In fact, elevated miRNA-21 level is powerful indicator of IBD exacerbation, miRNAs-19b, -192, and -215 were decreased in IBD, while miRNA-21, -19b, -192, and -215 were found as indicators of intestinal epithelial barrier function [33]. Ayyadurai et al. [37] reported that the miRNA 23b (known to be involved in IBD) was secreted and transported between cells to impose a gene-silencing effect on recipient intestinal macrophages and thereby it regulated intestinal epithelial repair. In opposite, the up-regulation of miRNA-155 (known as positive regulator of T-cell responses) is related to colitis-associated carcinogenesis, but is irrelevant to chronic intestinal inflammation [38]. Controversially, Min et al. [39] found that miRNA-155 appears to be elevated in patients with acute UC and plays a role in the intestinal inflammation by down-regulating the expression of FOXO3a.

There are evidences that over expression of hsa-miRNA-124a, hsa-miRNA-146a and hsa-miRNA-221/222 mediated the crosstalk within the Toll-like receptor signaling pathway may have predictive value for progression of intestinal-related chronic inflammation to cancer [40]. In this context, it is interestingly that higher methylation levels of miRNA-124a (known to have tumor-suppressive function) associates with elevated epidemiologic risk of colitis-associated cancer development in UC patients [41]. Moreover, investigators reported that methylation status of three miRNA-124a genes (miRNA-124a-1, -2, and -3) associated well with all types of intestinal neoplastic tissues. Down-regulated miRNA-133a and miRNA-143/145 was reported as biomarkers of human colorectal cancer in generally population and IBD patient cohort [42]. The spectrum of miRNAs that are involved in the pathogenesis of IBM is sufficiently wide. Whether are tissue specific miRNAs constructed specific phenotype of clinical presentation for IBD is not fully clear.

Whether is genome maps of circulating miRNAs useful for prediction of IBD development is not still clear. However, this is direction for further investigations. Overall, exosomal miRNA load assessment and exosomal miRNA profiling hold great promise for disease detection and monitoring.

Therefore, the data taken together may be helpful for risk stratification patients with IBD at several stages of the disease.
development and probably as indicator for target-based therapy of stratification patients with IBD at several stages of disease IBD.

<table>
<thead>
<tr>
<th>miRNAs</th>
<th>The potent role in IBD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Circulating miRNA-21</td>
<td>Increased level associates with risk of IBD exacerbation</td>
</tr>
<tr>
<td>Circulating miRNA 23b</td>
<td>Increased level associates with intestinal epithelial repair</td>
</tr>
<tr>
<td>Circulating miRNA-155</td>
<td>Increased level associates with risk of malignancy and tumorogenesis</td>
</tr>
<tr>
<td>Microvesicle-encapsulated miRNA-155</td>
<td>up-regulation was found in colitis-associated carcinogenesis and in patients with acute UC</td>
</tr>
<tr>
<td>Microvesicle-encapsulated miRNA-192</td>
<td></td>
</tr>
<tr>
<td>Microvesicle-encapsulated miR 495</td>
<td>Biomarker of NOD2 expression</td>
</tr>
<tr>
<td>Microvesicle-encapsulated miR 512</td>
<td></td>
</tr>
<tr>
<td>Microvesicle-encapsulated miR 671</td>
<td></td>
</tr>
<tr>
<td>Circulating miRNA-124/124a</td>
<td></td>
</tr>
<tr>
<td>Circulating miRNA-146a</td>
<td></td>
</tr>
<tr>
<td>Circulating miRNA-221/222</td>
<td></td>
</tr>
<tr>
<td>Circulating miRNA-133a</td>
<td>Down-regulated level is considered a biomarker of human colorectal cancer in generally population and IBD patient cohort</td>
</tr>
<tr>
<td>Circulating miRNA-143/145</td>
<td></td>
</tr>
<tr>
<td>Circulating miRNA-146a/146b</td>
<td>Biomarker of cell differentiation, growth</td>
</tr>
<tr>
<td>Circulating miRNA-122/126, Circulating miRNA-132</td>
<td></td>
</tr>
<tr>
<td>Circulating miRNA-21</td>
<td>Biomarker of intestinal epithelial barrier function</td>
</tr>
<tr>
<td>Circulating miRNA-150, Circulating miRNA-200b</td>
<td></td>
</tr>
<tr>
<td>Circulating miRNA-30c</td>
<td>Biomarker of autophagic activity</td>
</tr>
<tr>
<td>Circulating miRNA-130a</td>
<td></td>
</tr>
<tr>
<td>Circulating miRNA -106b</td>
<td></td>
</tr>
<tr>
<td>Circulating miRNA-93</td>
<td></td>
</tr>
<tr>
<td>Circulating miRNA-196</td>
<td></td>
</tr>
</tbody>
</table>

Table 2: The potent role of miRNAs in IBD development

**Abbreviations:** IBD: Inflammatory Bowel Diseases, UC: Ulcerative Colitis

**miRNA as Targeting for Therapeutic Strategy in Inflammatory Bowel Disease**

It is supposed that miRNA delivered by exosomes to specific cells by targeting with cell surface protein interaction may effect as biological regulator of metabolic processes. To achieve potential clinically significant utility circulating level of exosomes should be never less than $10^{10-12}$ exosomes/ml plasma. Although there is serious criticism regarding any perspective to use of microvesicle-encapsulated miRNAs, the therapeutic approaches toward regulation of function of intestinal cells in IBD patients is discussed broadly, but clinical trials regarding miRNA-related treatment program in IBD are absent [43]. However, potential translational applications of miRNAs are emerged attractive [43,44].

Therefore, there are evidences clarified that chronic inhibition of histone deacetylases and controlling for synthesis of wide spectrum isoforms of histone deacetylases via miRNAs may be useful for refractory patients with IBD [45]. Potential mechanism of positive effect for histone deacetylases inhibitors (valproic acid, vorinostat and givinostat) directly relates with reduction of pro-inflammatory cytokine release, increased apoptosis of immune competent cells, and regulation of transcription factors.

Consideration among clinical implementation of obtained data is required more clinical studies with higher statistical power and increased sample size. However, the novel therapeutic approach
associated with miRNA-related histone deacetylases inhibition appears to be attractive for clinical medicine.

**Conclusion**

In conclusion, we suggest that circulating miRNAs appear to be promising as possible biomarkers of IBD development and, probably, individualized indicator of response after treatment. The future of circulating miRNAs in reclassification of the patients with IBD is attractive.

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**Conflict of Interest**

None declare

**References**